GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap.

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Practice Guidelines

Background:

• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) updated its 2021 strategy report.
• Previously, "asthma-COPD overlap" (ACO) was a recognized term.
• GOLD now emphasizes asthma and COPD as distinct disorders that can coexist.

Purpose of the Study:

• To explore the implications of the revised GOLD guidance for treating physicians.
• To discuss the management of patients with coexisting asthma and chronic obstructive pulmonary disease (COPD).
• To advocate for a personalized treatment approach in these patients.

Main Methods:

• Review of the 2021 GOLD strategy report.
• Analysis of the clinical implications of differentiating asthma and COPD.
• Discussion of pharmacotherapy and non-pharmacological approaches for coexisting conditions.

Main Results:

• Asthma and COPD are now viewed as separate conditions, even when present in the same patient.
• Treatment for concurrent asthma should follow asthma guidelines.
• Additional pharmacological and non-pharmacological interventions may be necessary for the COPD component.

Conclusions:

• Physicians must adapt to the new GOLD guidance, moving away from the ACO concept.
• A personalized, individualized treatment plan is crucial for patients with both asthma and COPD.
• This approach ensures optimal management by addressing each condition appropriately.